Work

A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps5096

Authors: Himisha Beltran, Mark A. Rubin, Juan Miguel Mosquera, Paul J. Christos, Olivera Calukovic, Irene Karpenko, Jacek K. Pinski, Daniel Costin Danila, David M. Nanus, Scott T. Tagawa

Institutions: Weill Cornell Medicine, USC Norris Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602879607

Cites: 23

Cited by: 9

Related to: 10